Similarly, BIND-014, a prostate-specific membrane antigen (PSMA)-targeted docetaxel nanoparticle, showed promising early-phase results but failed in subsequent larger trials for prostate and lung cancers. This evidence concerns the gene FOLH1 and lung carcinoma.